Acorda Therapeutics Inc (ACOR) Insider Andrew A. Hindman Sells 753 Shares of Stock
Acorda Therapeutics Inc (NASDAQ:ACOR) insider Andrew A. Hindman sold 753 shares of Acorda Therapeutics stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $20.56, for a total value of $15,481.68. Following the completion of the sale, the insider now directly owns 5,171 shares in the company, valued at $106,315.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Acorda Therapeutics stock traded down $0.37 during trading hours on Friday, hitting $18.44. The company’s stock had a trading volume of 25,286 shares, compared to its average volume of 489,274. Acorda Therapeutics Inc has a twelve month low of $15.60 and a twelve month high of $36.35. The firm has a market cap of $882.21 million, a PE ratio of 17.90 and a beta of 1.45. The company has a quick ratio of 3.95, a current ratio of 4.03 and a debt-to-equity ratio of 0.57.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.15. Acorda Therapeutics had a positive return on equity of 13.72% and a negative net margin of 24.88%. The business had revenue of $142.80 million for the quarter, compared to analyst estimates of $82.74 million. During the same quarter in the prior year, the company posted $0.43 EPS. The company’s quarterly revenue was up 1.2% on a year-over-year basis. As a group, equities analysts expect that Acorda Therapeutics Inc will post 0.08 earnings per share for the current year.
A number of equities analysts have weighed in on ACOR shares. Cantor Fitzgerald started coverage on Acorda Therapeutics in a research note on Thursday, August 23rd. They set a “neutral” rating and a $32.00 price objective on the stock. JPMorgan Chase & Co. set a $20.00 price objective on Acorda Therapeutics and gave the stock a “hold” rating in a research note on Monday, September 10th. ValuEngine lowered Acorda Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 11th. BidaskClub lowered Acorda Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, HC Wainwright set a $31.00 price objective on Acorda Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 11th. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $26.56.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/acorda-therapeutics-inc-acor-insider-andrew-a-hindman-sells-753-shares-of-stock/2668197.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
Further Reading: Return on Equity (ROE)
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.